A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients

Clinical Infectious Diseases

Volumn 37, Issue 5, 2003, Pages 634-643

  Pappas, Peter G ^a,k   Rex, John H ^b   Lee, Jeannette ^a   Hamill, Richard J ^l   Larsen, Robert A ^j   Powderly, William ^c   Kauffman, Carol A ^d   Hyslop, Newton ^e   Mangino, Julie E ^f   Chapman, Stanley ^g   Horowitz, Harold W ^h   Edwards, John E ⁱ   Dismukes, William E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e TULANE UNIVERSITY   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^h WESTCHESTER MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k University of Alabama at Birmingham Hospital   (United States)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ADULT; ADULT DISEASE; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDIASIS; CHILDHOOD DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FUNGUS ISOLATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; INFANT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; UNITED STATES;

EID: 0042331368     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/376906     Document Type: Article

References (52)

1. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States. National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167:1247-51.
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29:239-44.
3. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of morbidity. Clin Infect Dis 1992; 15:414-21.
4. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29:1164-70.
5. Karabinis A, Hull C, Leclercq B, et al. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988; 26:429-32.
6. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11:379-90.
7. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999; 27:520-32.
8. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44:747-51.
9. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn Microbiol Infect Dis 1999; 35:19-25.
10. Rangel-Frausto MS, Wilbin T, Blumberg HM, et al. National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29:253-8.
11. Wright WL, Wenzel RP. Nosocomlal Candida: epidemiology, transmission, and prevention. Infect Dis Clin N Amer 1997; 11:411-25.
12. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospitalacquired candidemia. Arch Intern Med 1988; 148:2642-5.
13. Blumberg HM, Jarvis WR, Soucie M, et al. Risk factors of candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 2001; 33:177-86.
14. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, and the National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35:627-30.
15. Wey SB, Mori M, Pfaller MA, Woolsen RF, Wenzel RP. Risk factors for hospital-acquired candidemia. Arch Intern Med 1989; 149:2349-53.
16. Nucci M, Silveira MI, Spector N, et al. Risk factors for death among cancer patients with fungemia. Clin Infect Dis 1998; 27:107-11.
17. Pelz RK, Lipsett PA, Swoboda SM, et al. Candida infections: outcome and attributable ICU costs in critically ill patients. J Intensive Care Med 2000; 15:255-61.
18. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27:781-8.
19. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20:1531-4.
20. Yamamura DL, Rotstein C, Nicole LE, Ioannou S. Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registery of the Canadian Infectious Disease Society. Canadian Med Assoc J 1999; 160:493-9.
21. Viscoli C, Girmenia, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28:1071-9.
22. Colombo AL, Nucci M, Salomao R, et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34:281-6.
23. Rennert G, Rennert HS, Pitlik S, Finkelstein R, Kitzes-Cohen R. Epidemiology of candidemia - a nationwide survey in Israel. Infection 2000; 28:26-9.
24. Nguyen MH, Peacock JE, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100:617-3.
25. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325-30.
26. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 1997; 16:337-45.
27. Fichtenbaum CJ, German M, Dunagan, et al. A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B. Clin Infect Dis 1999; 29:1551-6.
28. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole vs. amphotericin B and review of the literature. Clin Infect Dis 1996; 23:964-72.
29. Dato VM, Dajani AS. Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy. Pediatr Infect Dis 1990; 9:309-14.
30. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic patients. Clin Infect Dis 2003; 36:1221-8.
31. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662-78.
32. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-8.
33. Kossof EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17:504-8.
34. Friedman S, Richardson SE, Jacobs SE, O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000; 19:499-504.
35. Huang YC, Lin TY, Leu HS, Peng HL, Wu JH, Chang HY. Outbreak of Candida parapsilosis fungemia in neonatal intensive care units: clinical implications and genotyping analysis. Infection 1999; 27:97-102.
36. Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20:571-5.
37. Weems JJ, Chamberland ME, Ward J, Willy M, Padhye AA, Solomon SL. Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol 1987; 25:1029-32.
38. Plouffe JF, Brown DG, Silva J, Eck T, Stricof RL, Fekety FR. Nosocomial outbreak of Candida parapsilosis fungemia related to intravenous infusions. Arch Intern Med 1977; 137:1686-9.
39. Weems JJ. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992; 14:756-66.
40. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22(Suppl 2):S89-94.
41. Waggoner-Fountain LA, Walker MW, Hollis RJ, et al. Vertical and horizontal transmission of unique Candida species to premature newborns. Clin Infect Dis 1996; 22:803-8.
42. Sobel JD, Ohmit SE, Schuman P, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (H1V)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2001; 183:286-93.
43. Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989; 87:614-20.
44. MacDonald L, Baker C, Chenoweth C. Risk factors for candidemia in a children's hospital. Clin Infect Dis 1998; 26:642-5.
45. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. Pediatr Infect Dis J 2000; 19:319-24.
46. Weese-Mayer DE, Fondriest DW, Brouillette RT, Shulman ST. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatri Infect Dis J 1987; 6:190-6.
47. Rowen JL, Rench MA, Kozinetz CA, Adams JM, Baker CJ. Endotracheal colonization with Candida enhances risk of systemic candidiasis in very low birth weight neonates. J Pediatr 1994; 124:789-94.
48. Andriole VT, Hasancleven ITF. Factors influencing experimental candidiasis in mice. Yale J Biol Med 1962; 35:96-112.
49. Goldstein E, Grieco MH, Finkel G, Louria DB. Studies on the path-ogenesis of experimental Candida parapsilosis and Candida guilliermondii infections in mice. J Infect Dis 1965; 111:293-302.
50. Cassone A, DeBernardis F, Pontieri E, et al. Biotype diversity of Candida parapsilosis and its relationship to the clinical source and experimental pathogenicity. J Infect Dis 1995; 171:967-75.
51. Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001; 32:1018-23.
52. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32:1191-200.